CME Sponsor:
MS-Leaders.org

Location:
Web-based material

Course Directors/Instructors:
Johns Hopkins Chair:
Scott Newsome, DO
Assistant Professor of Neurology
Johns Hopkins University School of Medicine
Baltimore, MD

Moderator
Michael Racke, MD
Professor and Chair, Department of Neurology
The Helen C. Kurtz Chair in Neurology
Ohio State University Medical Center
Columbus, OH

Faculty
Timothy Vollmer, MD
Professor of Neurology
University of Colorado Medical School
Co-Director of the Rocky Mountain MS Center at Anschutz
Medical Director Rocky Mountain MS Center
Denver, CO

Dean Wingerchuck, MD
Professor of Neurology
Vice-Chair, Clinical Research
Department of Neurology
Division of Multiple Sclerosis and Autoimmune Neurology
Mayo Clinic
Scottsdale, AZ

Number of Credits:
1.5 AMA PRA Category 1 Credits™

Registration Fee: Free

More Info

Detailed Description:
With a growing artillery of potential multiple sclerosis (MS) therapies, it becomes increasingly important for clinicians to recognize that MS therapy requires a two-tiered strategy, focusing on implementation of appropriate therapies that may not only reduce relapse frequency, but that may also provide neuroprotection.  With a clear comprehension of the potential neuroprotective properties of existing and emerging MS therapies, as well as of potential remyelinating agents on the horizon, clinicians will not only be better empowered to make tailored therapeutic decisions for their patients, but have the understanding necessary to discuss this aspect of MS therapy with their patients.  Being able to appropriately highlight the neuroprotective component of MS therapy to patients may hopefully help improve patient compliance, especially in those who feel their MS is ‘well-controlled’ and perhaps may even have concerns that continued MS treatment may not be justified.

Learning Objectives:
After viewing the program, the participant should demonstrate the ability to:
  • Discuss the importance of neuroprotective strategies in the management of MS
  • Describe the neuroprotective properties of currently available MS therapies and emerging MS therapies currently under investigation
  • Apply principles of neuroprotection in patient counseling to support starting disease modifying therapy, continuing therapy and escalating therapy when appropriate
  • Explain the goal of neuroregeneration in the management of MS
  • List two approaches under investigation for neuroregeneration in the management of MS
Intended Audience:
Health care professionals with roles in the diagnosis and treatment of multiple sclerosis